Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net loss	$ (16,647,875)	$ (20,942,737)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	763,840	1,611,521
Compensation associated with issuance of stock options	1,619,115	3,987,588
Impairment of goodwill and intangible assets	4,205,000
Accretion of royalty liability	61,050
Changes in assets and liabilities:
Decrease in accounts receivable	1,329,587	4,434,808
Increase in prepaid expenses and other current assets	(172,528)	(63,158)
Decrease in other assets	88,507	11,214
(Decrease) increase in accounts payable and accrued expenses	(1,218,345)	622,443
Increase (decrease) in deferred revenue	658,347	(1,975,963)
(Decrease) increase in royalty liability	(103,900)	116,103
(Decrease) increase in other long-term liabilities	(16,960)	27,686
Net cash used in operating activities	(9,434,162)	(12,170,495)
Cash flows from investing activities:
Acquisition of property and equipment	(165,860)	(145,197)
Internal-use software development costs	(226,000)
Net cash used in investing activities	(391,860)	(145,197)
Cash flows from financing activities:
Payments on capital lease obligation	(44,658)	(53,536)
Proceeds from employee stock purchase plan	171,796	474,233
Proceeds from exercise of warrants		320,500
Proceeds from employee stock option exercises	42,039	79,503
Net proceeds from issuance of common stock	9,389,626	10,273,003
Net cash provided by financing activities	9,558,803	11,093,703
Net decrease in cash and cash equivalents	(267,219)	(1,221,989)
Cash and cash equivalents at beginning of period	2,112,769	3,385,035
Cash and cash equivalents at end of period	1,845,550	2,163,046
Non-cash financing activities:
Issuance of common stock for developed technology	500,000
Cashless exercise of warrants		404
Cash paid during the period for:
Interest	$ 97,308	$ 89,100